European Archives - Page 833 of 899 - European Medical Journal

EMJ

Phase 3 trial of eribulin versus dacarbazine in leiomyosarcoma and liposarcoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium…

EMJ

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results…

EMJ

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses…

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty

Functional mitral regurgitation (FMR) is a common occurrence in patients with heart failure (HF). FMR is associated with as much as a 2-fold increase in…

EMJ Interventional Cardiology 3.1 2015

Welcome to this edition of European Medical Journal Interventional Cardiology, which we hope will provide you with a thorough analysis of some of the…

EMJ

AndraTec Optimus & Optimus Covered XL Stents a Novel Technology Stent Device

In the daily practise of an interventional paediatric cardiologist we often miss adequate material to treat complex lesions in vessel stenosis.

EMJ

Second-Line Cetuximab Active beyond Progression in Quadruple Wild-Type Patients with Metastatic Colorectal Cancer

BARCELONA-LUGANO, 4 July 2015 – Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes…

EMJ

Sex and Musculoskeletal Health in Tandem

GENDER differences between males and females have been found to extend to their bone and joint conditions, while improved education of patients and…

EMJ

Gene Regulates Stem Cells in Muscle Regeneration

PROTEIN called Prmt5 is key to the regulation of the activity and function of muscle stem cells in injured skeletal muscles, as revealed by researchers…

SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma

An update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.